

10-K Checklist

Research Analysts

David Zion, CFA, CPA

212 538 4837

david.zion@credit-suisse.com

Amit Varshney, CFA, FRM

212 538 8049

amit.varshney@credit-suisse.com

Nichole Burnap, CPA

212 325 5417

nichole.burnap@credit-suisse.com

ACCOUNTING



Source: Steve Kelley Editorial Cartoon used with the permission of Steve Kelley and Creators Syndicate. All rights reserved.

- **Our sports gene test came back marked “accountant,” too,** that’s why we’re writing about 10-Ks instead of catching alley-oops from Jeremy Lin. For those slogging through hundreds of pages of 10-Ks this season we suggest taking a peek at our *10-K Checklist* to help focus your reading.
- **We kickoff the tenth annual 10-K Checklist** with Exhibit 1 (a list of the items that companies are required to provide in a 10-K) and end with Exhibit 3 (a list of the exhibits that you might find attached to the 10-K). In between we focus on the Management Discussion and Analysis (MD&A), Financial Statements and Footnotes, including disclosures to keep an eye on and some questions to consider as you try to digest all the information crammed into the 10-K.
- **10-Ks are due leap day (we can’t think of a better way to spend the extra day)** for large (over \$700 million public float) calendar year end companies.

DISCLOSURE APPENDIX CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, INFORMATION ON TRADE ALERTS, ANALYST MODEL PORTFOLIOS AND THE STATUS OF NON-U.S ANALYSTS. FOR OTHER IMPORTANT DISCLOSURES, visit www.credit-suisse.com/researchdisclosures or call +1 (877) 291-2683. U.S. Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Exhibit 1: What's in the 10-K

| Item # | Item Name | Our Thoughts |
|-----------------|---|--|
| <i>Part I</i> | | |
| 1 | Business | If you are not sure what the company does for a living, check here. |
| 1A | Risk Factors | Have you factored these risks into your analysis when valuing the company? If not, you probably should. Also keep an eye out for any new risk factors and how the company manages risk. |
| 1B | Unresolved Staff Comments | Look here to find out if the SEC staff has made any comments to the company that are still up in the air. |
| 2 | Properties | If you want to know how many properties the company has, or how many square feet it occupies, where they are and whether the properties are leased or owned, you may be able to find it here. |
| 3 | Legal Proceedings | Look here to find out if the company is in court and why. You can also find out if the company had to pay the IRS any penalties related to tax shelters. |
| 4 | Mine Safety Disclosures | Here is where mine operators will tell you about specific health and safety violations, orders and citations, related legal actions and assessments, and mining-related fatalities. |
| <i>Part II</i> | | |
| 5 | Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities | A good source for information about the company's share buybacks, including the number of shares repurchased and average price paid during the 4 th quarter. |
| 6 | Selected Financial Data | The five year summary, includes, revenues, EPS, assets, long-term debt, and other data. Sometimes includes industry-specific metrics. |
| 7 | Management's Discussion and Analysis of Financial Condition and Results of Operations | Where management is supposed to tell you in its own words what's going on with the business. (More detail below) |
| 7A | Quantitative and Qualitative Disclosures About Market Risk | How exposed is the company to interest rate, foreign currency, commodity price and other market risks. They may even give you a rough idea of how they hedge. |
| 8 | Financial Statements and Supplementary Data | The financial statements and footnotes that we all know and love. The audit opinion is here too. (More detail below) |
| 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | If the company and its accountants disagree on something, the dirty laundry is aired here. (Rarely used) |
| 9A | Controls and Procedures | Find out more about the company's internal accounting controls and whether they appear to be working or not. Descriptions of any "material weaknesses" should be included here. |
| 9B | Other Information | Companies can disclose something here instead of filing an 8-K. In other words it's worth a peek. |
| <i>Part III</i> | | |
| 10 | Directors, Executive Officers and Corporate Governance | Curious as to who runs the company, check here. Most times it will refer you to the proxy. |
| 11 | Executive Compensation | Show me the money. |
| 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | Find out how many shares are owned by "insiders" (i.e. senior management, the board and big shareholders (more than 5%)). |
| 13 | Certain Relationships and Related Transactions, and Director Independence | What's a few dollars between friends? Maybe a lot, actually. You should take a look at any related party transactions. |
| 14 | Principal Accountant Fees and Services | How much are the accountants getting paid and what are they getting paid to do. Look for possible conflicts of interest. |
| <i>Part IV</i> | | |
| 15 | Exhibits and Financial Statement Schedules | A laundry list that could include, certificate of incorporation, bylaws, indentures, deferred compensation plan, etc. A good place to find important contracts. Often included by reference. Check out Exhibit 3 for more details. |
| Signatures | | The lucky few that get to sign off on this thing. |

Source: U.S. Securities and Exchange Commission, Credit Suisse Accounting & Tax Research

10-K Checklist

Management Discussion and Analysis (MD&A)

Of all the sections in the 10-K, it's the MD&A that has the most forward looking information which allows management to discuss and analyze the material trends, demands, commitments, events and uncertainties that are facing the business (this year keep an eye out for additional disclosures around European sovereign debt exposures). It is also where investors should be getting information about what's driving the results and the quality of earnings and cash flows (i.e., are they sustainable and from the core business). Just a reminder though; unlike the financial statements and footnotes, the MD&A is not audited.

- *Liquidity and capital resources.* As cash continues to pile up on the balance sheets of Corporate America investors want to know where it's located. Because if its parked overseas it may not be readily available as a source of liquidity to pay a dividend, buy back stock, etc. and the company may have to take a big tax hit to get its hands on the cash (as a result you might want to apply a cash haircut). In response the SEC has been pushing companies to disclose the amount of cash and short-term investments held by foreign subsidiaries. We're expecting more companies to start making this a standard disclosure this 10-K season, last year we were only able to find 54 companies in the S&P 500 that disclosed where in the world their cash was located (see our April 26, 2011 report for a further discussion, *Parking Earnings Overseas, \$1.3 Trillion Parking Lot for the S&P 500*). Other items to keep an eye out for in this section are more detail about the sources and uses of cash (beyond the amounts that show up on the cash flow statement) and a discussion of where intraperiod borrowings differ from end of period amounts. Does the company have any unused lines of credit? Do they securitize or factor receivables? Also look for companies to discuss covenants including what could trip them and the consequences.
- *Contractual obligations.* Look for a table and description of the expected timing and amounts due under contractual obligations; in other words, cash that's contractually obligated to go out the door in the future. The table includes obligations that are on balance sheet (e.g., debt) and off-balance-sheet (e.g., operating leases). Even though the data is far from perfect we still think it's a good starting point for gauging a company's liquidity and capital resource needs. Have you worked these cash outflows into your model? Is there refinancing risk? Does the contractual obligations data provide you with any insight about forward capex and/or revenue? Compare the contractual obligations to cash balances to measure a company's cash cushion and determine whether it really has excess cash (for a further discussion see our May 31, 2011 report, *How Big is the Cash Cushion? Cash Vs. Contractual Obligations*).
- *Critical accounting estimates.* If you're on the look out for accounting red flags this is a good place to start. It's where companies are supposed to discuss their "critical" accounting estimates that have the biggest impact on the financial statements and involve the greatest degree of management judgment (a management team looking to manipulate its results might start with these estimates and assumptions). We would recommend keeping a close watch on them and asking some questions: Do the assumptions make sense? Are they aggressive or conservative? How do they stack up against prior years and peers? Have they left anything out? If the assumptions have changed, is it the changed assumptions or underlying performance of the business that are driving results? Companies are also supposed to provide (though they rarely do) sensitivity analyses—what happens to the financial statements if these estimates are changed (have you worked this into your model)?
- *Off-balance-sheet activity.* With the accounting rule changes bringing more off-balance-sheet transactions on balance sheet this disclosure has changed. We have noted less discussion on SPEs and more details on contracts, transactions and

agreements with customers, vendors, lessors, asset purchasers, and investees (including guarantees). For the stuff that's remained off-balance-sheet ask yourself if it's the result of the underlying economics or a clever structure designed to get around the new rules. (See our April 7, 2010 research report, *Off Again, On Again? The Effect of New Off-Balance-Sheet Rules* for a further discussion.) Also question whether the off-balance-sheet transactions make sense? Do they have a valid business purpose? Should you bring them back on balance sheet from an analytical perspective (in most cases, yes)? Have you factored the risks from this activity into your analysis (companies may even disclose the amount of loss they could incur as a result of an off-balance-sheet entity)?

Financial Statements

You all have your favorite ways to slice and dice the financial statements, our simple suggestion is that no matter what type of analysis you are doing take a step back and try to understand what's driving the improved margins, reduced leverage, growth in revenues, etc. Is it the underlying economics or some type of accounting hocus pocus?

- *Balance sheet.* Are the assets and liabilities fairly stated? Take a look at the capital structure, how has the company financed itself? Is the balance sheet overly levered, overly complicated, why? What are all the claims on cash flow that might stand ahead of yours? Does the company have adequate liquidity? Have you factored in the company's off-balance-sheet arrangements into your analysis (a healthy looking balance sheet may not appear so healthy after you do)? Asset liability mismatches (long-duration assets paired with short-duration liabilities, and vice versa) have caused problems over time, don't forget about them and make sure to factor the associated risks into your analysis?
- *Statement of changes in shareholders' equity.* This is probably the most underrated of the financial statements, however, it includes useful information about dividends, share repurchases and share issuance. Don't forget about accumulated other comprehensive income too, the dumping ground for things that are volatile; including gains and losses from foreign currency translation, cash flow hedges and available for sale securities along with changes in pension funded status. Try to get an idea as to when these gains and losses might eventually make their way onto the income statement and whether they provide any incremental insight into real economic risks that a company is facing. Remember, starting in the first quarter other comprehensive income (OCI) will be presented either on the face of the income statement or in a separate statement immediately following (that may result in OCI showing up in some earnings releases and getting more attention than it does today).
- Also, compare the financial statement presentation to the prior year. Has it changed? Are you seeing different line items? If so, why? Don't forget to take a look at the audit opinion and management's report on internal controls. Did the auditor note any "significant deficiencies" or "material weaknesses"?

Footnotes

Much of our time is spent trolling through the footnotes searching for nuggets of information that help us to better understand what's going on in the financial statements. We have included some of our favorite footnotes below, how much time you spend on each will vary by company.

- *Pensions.* Last year was a tough one for many defined benefit pension plans as they were battered by falling interest rates and a weak stock market. As a result we estimated that pension underfunding increased significantly. How did the funded status of the plans change, was it as expected? We have noticed some plans outperforming our expectations, in part due to strong asset performance. Was that the

result of having a heavier mix of long duration fixed income assets (whether in cash securities or synthetically through derivatives), picking the right asset managers, or optimistically valuing hard to value assets? We'd also suggest keeping a close watch on the discount rate (there appears to be wide variation across companies in how much the discount rate changed during 2011). Does the discount rate appear aggressive relative to yields on high grade bonds, peers, etc.? If so what would the underfunding look like if a more conservative rate were used? Has the company frozen the pension plan? If so what type of benefit was it replaced with (e.g., 401-K) and what's the cost? Pension risk comes in a number of flavors, the question is: Are you willing to pay for companies to take it on? There are risks associated with an asset liability mismatch, has the company done anything with its asset allocation to try and better manage the risks in the plan? Or is it looking to offload its pension risk on the plan participants through a lump sum or on an insurance company by buying an annuity? There is also liquidity risk; how much will the company have to contribute to its pension plan and when? We are estimating pension contributions will increase in 2012. If you are more concerned with pension costs, check whether the expected rate of return on plan assets appears reasonable, especially if the company has changed its asset allocation. Has the company lengthened the amortization period used to recognize actuarial gains and losses that could soften the blow to earnings from higher pension costs? Or has the company decided to dump the smoothing and go to a full mark-to-market approach? For a further discussion see our January 10, 2012 report, *Pensions Punished, Look for Pension Contributions to Go Up*.

- *Multiemployer pension plans* are becoming less of a black box as companies will be providing new disclosures about these plans for the first time this 10-K season (in fact we have already found at least 10 companies in the S&P 500 that appear to be providing the new disclosure). The disclosures include information about the health of each significant multiemployer plan by disclosing funding zones, green (over 80% funded), yellow (between 65% and 80% funded) and red (below 65% funded). Companies will also tell you the amount contributed to the plans and whether their contribution was more than 5% of the total contributions made to the plan. If you want to dig deeper the name and tax ID number of the plans will be provided, which you can use to find the publicly available form 5500 filing (the annual report for the pension plan filed with the IRS) which includes information about the funded status of the plan, plan assets, assumptions, etc. (If you need any help finding or analyzing 5500 filings, don't hesitate to give us a call).
- *Taxes*. The tax footnote is a goldmine of information. Does the effective tax rate make sense? If the effective tax rate is low, why is it low and is it sustainable (think about how much credit you are giving the company for having a low tax rate in your valuation)? What effect have taxes had on earnings and cash flows? How valuable are the deferred tax assets, don't forget to take into account timing? When do the operating/capital loss carryforwards and tax credit carryforwards expire? Will the company have to set up a deferred tax valuation allowance? If a valuation allowance exists when will it be reversed, providing a boost to earnings and book value? What is the total amount of undistributed foreign earnings? Does the company have enough liquidity to continue making the assertion that earnings are permanently reinvested overseas? What would the U.S. tax provision be on those earnings if the company tried to bring them back to the U.S. (it's an off-balance-sheet tax liability)? (See our April 26, 2011 report, *Parking Earnings Overseas, \$1.3 Trillion Parking Lot for the S&P 500*.) How much of a boost to cash flow did the company get from bonus depreciation? (See our December 10, 2010 report, *A Gift from Uncle Sam, 100% Bonus Depreciation*.) We also suggest a close look at the disclosures on uncertain tax positions or unrecognized tax benefits as it may highlight a company's tax risk. For further discussion, see our May 18, 2007 report, *Peeking behind the Tax Curtain, FIN 48 Reveals Tax Risk*. You might have to look outside the tax footnote to find cash taxes paid, once you do, figure out the cash tax rate and compare cash taxes to book

taxes. In addition the SEC would like companies to reveal the amount of pre-tax profit and effective tax rates in countries with “very low tax rates.”

- **Derivatives.** When a company suggests that you ignore the gains/losses on an “economic” hedge ask yourself why they weren’t able to get hedge accounting treatment in the first place. Is it due to the frightening complexity of the accounting or that the company was unable to prove a high correlation between the hedged item and the derivative? You may also want to pay attention to hedge “ineffectiveness” (which many companies try to gloss over) since it represents economic gains and losses and could be a sign that a company is having some difficulty managing their risks. Look for disclosures about (1) How and why the company uses derivatives (2) How derivatives and hedged items are accounted for and (3) How derivatives and hedged items impact the financial statements. While the disclosures are far from ideal they may help you better understand a company’s derivatives usage. How does the gross derivative exposure compare to the net amount on the balance sheet? Does this change your view of the company’s leverage? After adjusting for netting, how do U.S. companies compare to their international peers that follow IFRS (and have less netting)? For a further discussion see our January 28, 2011 report, *Grossing Up the Balance Sheet, Nearly \$7 Trillion of Derivative Assets and Liabilities Could Land on Balance Sheet*.
- **Financial instruments.** New troubled debt restructuring (TDR) rules were adopted in 2011. How many modifications were treated as TDRs as a result of the new rules and what impact did that have on the allowance for loan losses? (See our April 6, 2011 report, *Troubled Debt Restructurings, New Rule Could Result in More Loan Modifications Treated as TDR*). Also look for new disclosures about TDRs that took place during the past year and the TDRs that defaulted during the period. Don’t forget to keep an eye on how the spread between fair value and cost of financial instruments changed year-over-year. Did the fair values improve or deteriorate? Do the fair values make sense, especially for Level 3 assets and liabilities? Does the company have any underwater securities that it hasn’t impaired yet? Look for the disclosure where companies highlight the debt and equity securities that have been trading below their cost basis for more than 12 months. Examine the information about the credit quality of loans (including the aging schedule and loans on nonaccrual status).
- **Foreign currency.** If you’re going to adjust the results to strip out currency when it has a negative impact make sure you make the same type of adjustments when currency turns positive. What effect have foreign currency movements had on earnings, revenues, margins etc.? Which currencies are the results most sensitive to? Have currency exposures changed? How does the company manage FX risk? What amount of FX risk remains unhedged?
- **Commitments and contingencies.** After issuing lots of comment letters over the past few years to improve transparency around contingent claims, the SEC wants to cut down on contingency related surprises and has reminded companies that disclosures should evolve as fact patterns evolve. As a result look for companies to provide more substantive disclosures about contingent losses in advance of recognizing a loss including an estimated range of loss if a contingent loss is reasonably possible. Remember, these are potential claims on the company’s cash flow, how have you factored them into your analysis? How do these claims stack up against the company’s cash flow generating ability and resources? What might trigger a commitment or contingency becoming a cash outflow for a company?
- **Acquisitions.** Take a look at the footnotes and see if you can figure out what the company bought, how much they spent and whether they overpaid. How was the transaction financed? What was the business case for the deal? Does the allocation of purchase price make sense (e.g., are excessive amounts allocated to goodwill)?

- **Reserves.** Keep an eye on the restructuring reserve, allowance for loan losses, allowance for doubtful accounts, inventory valuation allowance, warranty reserve, deferred tax valuation allowance, and all the stuff in Schedule II *Valuation and Qualifying Accounts* (which is typically found following the footnotes). Are these items being used to smooth or manage earnings?
- **Fixed assets / intangibles (including goodwill).** Has there been a change in amortizable or depreciable lives and if so what impact has it had on earnings? Is the change reasonable? Are the assets impaired? Remember impairments could change investor expectations about future cash flows and it may even cause a company to trip over covenants. If a company has impaired goodwill the SEC would like to see a discussion about what the impairment means, for example, what has gone wrong since the acquisition and what it says about the future cash flow generating ability of the business (as opposed to just highlighting that its “non-cash”). Keep in mind that this year the goodwill impairment test is changing from a purely quantitative assessment to a more qualitative one (don’t be surprised to see a drop off in goodwill impairments as a result).
- **Employee stock options.** How have you factored stock based compensation into your valuation of the company, especially if the cost is being backed out to arrive at pro forma EPS and the earnings dilution is being papered over by share buybacks? How much of a claim do the option holders have on your stake in the company? We suggest pricing the outstanding stock options to figure it out. How much wealth is being transferred from you to the employees when options are exercised? Has the company made any changes to its stock based compensation plans, is it using more performance based options? If so, are the performance metrics ones that you think drive shareholder value? Do the option pricing assumptions make sense? What impact have changing assumptions had on reported results? What amount of option compensation cost was recognized in the income statement, how does that compare with the economic cost of the plans? Do management and the Board exclude equity based compensation when evaluating results, budgeting, planning, comparing to peers, and determining incentive pay? If so, why? See our January 20, 2006 report, *The Cost of Employee Stock Options, Part II* for a further discussion.
- **Other postretirement employee benefits (OPEB).** Has the company set aside any assets to pay OPEB benefits, if so, for how many years could plan assets be used to pay benefits before it comes out of corporate cash flow? Compare the OPEB benefits that the company is expecting to pay (companies provide a ten year forecast) to your cash flow projections. How have you factored that cash outflow into your valuation? Also, ask yourself whether the assumptions make sense (e.g., healthcare inflation rate)? Has the company made any changes to the OPEB plan, increased cost sharing with retirees, offloaded the plan on a union, closed the plan to new employees or frozen it?
- **Leases.** The FASB and IASB are still working on lease accounting. Eventually (2015 at the earliest) most leases (except short-term) will come on balance sheet. While the effective date seems far off, companies are starting to talk about the change being a risk in their financial statements. You may want to get a head start and, at the very least, get your hands on the future minimum lease payments to try to estimate the size of the off-balance-sheet lease liability and asset along with the potential impact on earnings. For details see our August 17, 2010 report, *Leases Landing on Balance Sheet, Proposed Major Changes to Lease Accounting*.
- **Accounting motivated / significant transactions.** If you read an overly complex description of a transaction and you can’t understand why it was done (even after rereading the disclosure five times), something should at a minimum not smell right ... was the transaction designed to achieve a particular accounting result? How would

results change if the structure changed? Is there an economic reason for the structure? Is the company incurring an economic cost to reduce an accounting cost or to try and paint a prettier picture of the business? Have any other companies executed a similar transaction and what were the results?

- *Summary of significant accounting policies.* In the first footnote, we recommend looking for any changes in accounting policy, either voluntary or required. We would also compare the accounting policies to the peer group. Do the policies make sense? Do they best reflect the underlying economics of the business? What impact will new accounting rules have on the financial statements? For some companies adopted new revenue recognition standards early, but in 2011 all companies were required to adopt changes made to the milestone method (ASU 2010-17), multiple deliverable arrangements (ASU 2009-13), and agreements with software elements (ASU 2009-14). How will revenue recognition patterns change as a result of the new rules and what does it mean to margins and earnings? For further discussion, see our September 10, 2009 report, *Revenue Timing Could Change...for Arrangements with Multiple Deliverables*. Also, insurance companies should provide disclosures around the adoption of ASU 2010-26 which will result in fewer costs capitalized as part of deferred acquisition costs (DAC) starting this year. Look for companies to discuss the impact on book value if they chose to write-off previously capitalized DAC that didn't meet the new requirements and how future margins may be impacted by the new rule. For further discussion see our July 29, 2010 report, *US Life Insurance, Tracking the New DAC, FASB Likely to Approve New Rules for DAC*.
- *Other.* Take a look at what is included in other income/expense and other assets/liabilities (e.g., other accrued expense); you never know what you might find.

Due Date

The 10-K filing deadline varies depending upon a company's public float as you can see in Exhibit 2. For calendar year companies that are large accelerated filers the 10-Ks are due on Wednesday while the accelerated filers have a March 15 filing deadline. For calendar year companies that are non-accelerated filers the 10-Ks are due on March 30. The SEC recently decided to require foreign companies (regardless of their size) to file their 20-Fs within four months of the end of the year (down from 6 months), so for calendar year-end companies look for those bundles of fun by April 30.

Exhibit 2: Filing Deadlines

| Type of Filer | Public Float | 10-K Filing Deadline | 10-Q Filing Deadline |
|-------------------------|-------------------------------|-------------------------|---------------------------|
| Large Accelerated Filer | Above \$700 Million | 60 days after year-end | 40 days after quarter-end |
| Accelerated Filer | \$75 Million to \$700 Million | 75 days after year-end | 40 days after quarter-end |
| Non-Accelerated Filer | Below \$75 Million | 90 days after year-end | 45 days after quarter-end |
| Foreign Filers | All Foreign Issuers | 4 months after year-end | |

Source: U.S. Securities and Exchange Commission.

What Happens if a Company Misses the Filing Deadline?

The 10-K filing deadline can be automatically extended for 15 days; companies must file a notice of late filing with the SEC on form NT 10-K under rule 12b-25. Once you go beyond the 15 days, watch out, the stock could be subject to delisting, it can cause problems with covenants and investors might not like the uncertainty.

The Exhibits

Exhibit 3: Exhibits (Attached to the 10-K)

| Exhibit # | Exhibit Name | Our Thoughts |
|-----------|--|---|
| 2 | Plan of Acquisition, Reorganization, Arrangement, Liquidation or Succession | Look here for the finer details of a company's acquisitions, dispositions, reorganizations, etc. |
| 3(i) | Articles of Incorporation | Contains the official name of the company, state of incorporation, and details of the classes and series of shares (the number of shares authorized, shareholder rights, preferences and limitations, etc.) |
| 3(ii) | By-Laws | Has corporate governance details such as the composition of the board, length of a director's term, when and where annual meetings are to be held, officer job descriptions, how to amend by-laws, etc. |
| 4 | Instruments Defining the Rights of Security Holders, Including Indentures | These agreements contain the details related to debt and equity security rights which are especially important if the company has a complex capital structure and/or it's in distress. |
| 9 | Voting Trust Agreement | Describes a trust that holds a company's shares in another company and how the trustee is to oversee/manage/vote them. |
| 10 | Material Contracts | Fun legalese reading of contracts that are outside the ordinary course of business including: bridge loans, employment, joint ventures, leases, and equity awards. |
| 11 | Statement re: Computation of Per Share Earnings | If companies don't provide a detailed computation of basic and diluted EPS in their footnotes, look here. |
| 12 | Statement re: Computation of Ratios | Look here for the computation of earnings to fixed charges ratios and other ratios. |
| 13 | Annual Report to Security Holders | Our favorite exhibit, it's where you'll find the financial statements. |
| 14 | Code of Ethics | Just how ethical is that management team? |
| 16 | Letter re: Change in Certifying Accountant | A letter from the replaced auditor that notes any disagreements with the company. Companies don't change auditors often so this exhibit might be worth a look if it's filed. |
| 18 | Letter re: Change in Accounting Principles | When you see a change in accounting, ask yourself whether the new policy is aggressive/conservative, how it compares with peers, and how it will impact results. |
| 21 | Subsidiaries of the Registrant | A list of all subsidiaries and their jurisdiction of incorporation. Are the subs domiciled in countries where the company sells/manufactures its product or in countries with low tax rates? |
| 23 | Consent of Experts and Counsel | Permission to use an outside expert's statement, document, or opinion (e.g., a valuation expert's consent to use their valuations in the company's annual report). Are the "experts" reputable? How much does the company rely on third party experts and counsel in the preparation of their financial statements? |
| 24 | Power of Attorney | This document gives a few officers the authority to sign on behalf of all the individual directors. More of a procedural document. |
| 31(i)/32 | (i) Rule 13a-14(a)/ 15d-14(a) Certifications | Certifications by the CEO and CFO that the financial statements and internal controls are kosher. |
| 31(ii) | (ii) Rule 13a-14(d)/ 15d-14(d) Certifications | Asset-backed securities issuers certify the documents filed regarding servicing, distribution, and performance of the assets are true. |
| 33 | Report on Assessment of Compliance with Servicing Criteria for Asset-Backed Issuers | If not compliant, what does this mean for rest of the company? |
| 34 | Attestation Report on Assessment of Compliance with Servicing Criteria for Asset-Backed Securities | An auditor's report that agrees/disagrees with management's assessment of their compliance with the servicing of asset backed securities. |
| 35 | Servicer Compliance Statement | Applies only to a servicer and states that it has fulfilled its servicing agreement obligations and it is compliant. |
| 99 | Additional Exhibits | Any other exhibits the company wants to file. |
| 100/101 | XBRL-Related Documents/ Interactive Data File | The financial statements written in XBRL (eXtensible Business Reporting Language). The full power of this bar-coding for financial information will be realized when the tagging is more consistent. |

Source: U.S. Securities and Exchange Commission, Credit Suisse Accounting & Tax Research

Disclosure Appendix

Important Global Disclosures

David Zion, CFA, CPA, Amit Varshney, CFA, FRM & Nichole Burnap, CPA each certify, with respect to the companies or securities that he or she analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities.

Analysts' stock ratings are defined as follows:

Outperform (O): The stock's total return is expected to outperform the relevant benchmark* by at least 10-15% (or more, depending on perceived risk) over the next 12 months.

Neutral (N): The stock's total return is expected to be in line with the relevant benchmark* (range of $\pm 10-15\%$) over the next 12 months.

Underperform (U): The stock's total return is expected to underperform the relevant benchmark* by 10-15% or more over the next 12 months.

*Relevant benchmark by region: As of 29th May 2009, Australia, New Zealand, U.S. and Canadian ratings are based on (1) a stock's absolute total return potential to its current share price and (2) the relative attractiveness of a stock's total return potential within an analyst's coverage universe**, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. Some U.S. and Canadian ratings may fall outside the absolute total return ranges defined above, depending on market conditions and industry factors. For Latin American, Japanese, and non-Japan Asia stocks, ratings are based on a stock's total return relative to the average total return of the relevant country or regional benchmark; for European stocks, ratings are based on a stock's total return relative to the analyst's coverage universe**. For Australian and New Zealand stocks, 12-month rolling yield is incorporated in the absolute total return calculation and a 15% and a 7.5% threshold replace the 10-15% level in the Outperform and Underperform stock rating definitions, respectively. The 15% and 7.5% thresholds replace the +10-15% and -10-15% levels in the Neutral stock rating definition, respectively.

**An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.

Restricted (R): In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V]: A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.

Analysts' coverage universe weightings are distinct from analysts' stock ratings and are based on the expected performance of an analyst's coverage universe* versus the relevant broad market benchmark**:

Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

*An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.

**The broad market benchmark is based on the expected return of the local market index (e.g., the S&P 500 in the U.S.) over the next 12 months.

Credit Suisse's distribution of stock ratings (and banking clients) is:

| | Global Ratings Distribution | |
|---------------------------|-----------------------------|-----------------------|
| Outperform/Buy* | 46% | (60% banking clients) |
| Neutral/Hold* | 42% | (57% banking clients) |
| Underperform/Sell* | 10% | (49% banking clients) |
| Restricted | 2% | |

*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.

Credit Suisse's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research-and-analytics/disclaimer/managing_conflicts_disclaimer.html

Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

Important Regional Disclosures

Singapore recipients should contact a Singapore financial adviser for any matters arising from this research report.

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with Credit Suisse should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.

As of the date of this report, Credit Suisse acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

Principal is not guaranteed in the case of equities because equity prices are variable.

Commission is the commission rate or the amount agreed with a customer when setting up an account or at anytime after that.

CS may have issued a Trade Alert regarding this security. Trade Alerts are short term trading opportunities identified by an analyst on the basis of market events and catalysts, while stock ratings reflect an analyst's investment recommendations based on expected total return over a 12-month period relative to the relevant coverage universe. Because Trade Alerts and stock ratings reflect different assumptions and analytical methods, Trade Alerts may differ directionally from the analyst's stock rating.

The author(s) of this report maintains a CS Model Portfolio that he/she regularly adjusts. The security or securities discussed in this report may be a component of the CS Model Portfolio and subject to such adjustments (which, given the composition of the CS Model Portfolio as a whole, may differ from the recommendation in this report, as well as opportunities or strategies identified in Trading Alerts concerning the same security). The CS Model Portfolio and important disclosures about it are available at www.credit-suisse.com/ti.

Taiwanese Disclosures: Reports written by Taiwan-based analysts on non-Taiwan listed companies are not considered recommendations to buy or sell securities under Taiwan Stock Exchange Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers.

To the extent this is a report authored in whole or in part by a non-U.S. analyst and is made available in the U.S., the following are important disclosures regarding any non-U.S. analyst contributors:

The non-U.S. research analysts listed below (if any) are not registered/qualified as research analysts with FINRA. The non-U.S. research analysts listed below may not be associated persons of CSSU and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

For Credit Suisse disclosure information on other companies mentioned in this report, please visit the website at www.credit-suisse.com/researchdisclosures or call +1 (877) 291-2683.

Disclaimers continue on next page.



This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse AG, the Swiss bank, or its subsidiaries or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates.

The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients as its customers by virtue of their receiving the report. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. CS does not offer advice on the tax consequences of investment and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change.

CS believes the information and opinions in the Disclosure Appendix of this report are accurate and complete. Information and opinions presented in the other sections of the report were obtained or derived from sources CS believes are reliable, but CS makes no representations as to their accuracy or completeness. Additional information is available upon request. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, a trading call regarding this security. Trading calls are short term trading opportunities based on market events and catalysts, while stock ratings reflect investment recommendations based on expected total return over a 12-month period as defined in the disclosure section. Because trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may differ directionally from the stock rating. In addition, CS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. CS is involved in many businesses that relate to companies mentioned in this report. These businesses include specialized trading, risk arbitrage, market making, and other proprietary trading.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgement at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk.

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase.

Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment, in such circumstances you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed.

This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed the linked site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk.

This report is issued and distributed in Europe (except Switzerland) by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is regulated in the United Kingdom by The Financial Services Authority ("FSA"). This report is being distributed in Germany by Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). This report is being distributed in the United States by Credit Suisse Securities (USA) LLC ; in Switzerland by Credit Suisse AG; in Canada by Credit Suisse Securities (Canada), Inc.; in Brazil by Banco de Investimentos Credit Suisse (Brasil) S.A. or its affiliates; in Mexico by Banco Credit Suisse (México), S.A. (transactions related to the securities mentioned in this report will only be effected in compliance with applicable regulation); in Japan by Credit Suisse Securities (Japan) Limited, Financial Instrument Firm, Director-General of Kanto Local Finance Bureau (Kinsho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Securities Investment Advisers Association, Type II Financial Instruments Firms Association; elsewhere in Asia/Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse (Hong Kong) Limited, Credit Suisse Equities (Australia) Limited, Credit Suisse Securities (Thailand) Limited, Credit Suisse Securities (Malaysia) Sdn Bhd, Credit Suisse AG, Singapore Branch, Credit Suisse Securities (India) Private Limited regulated by the Securities and Exchange Board of India (registration Nos. INB230970637; INF230970637; INB010970631; INF010970631), having registered address at 9th Floor, Ceejay House, Dr.A.B. Road, Worli, Mumbai - 18, India, T- +91-22 6777 3777, Credit Suisse Securities (Europe) Limited, Seoul Branch, Credit Suisse AG, Taipei Securities Branch, PT Credit Suisse Securities Indonesia, Credit Suisse Securities (Philippines) Inc., and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse AG, Taipei Securities Branch has been prepared by a registered Senior Business Person. Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn. Bhd., to whom they should direct any queries on +603 2723 2020.

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the U.S.

Please note that this report was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA or in respect of which the protections of the FSA for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report.

Any Nielsen Media Research material contained in this report represents Nielsen Media Research's estimates and does not represent facts. NMR has neither reviewed nor approved this report and/or any of the statements made herein.

If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content.

Copyright 2012 CREDIT SUISSE AG and/or its affiliates. All rights reserved.

CREDIT SUISSE SECURITIES (USA) LLC
United States of America: +1 (212) 325-2000